Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Discerning the spatio-temporal disease patterns of surgically induced OA mouse models.

Haase T, Sunkara V, Kohl B, Meier C, Bußmann P, Becker J, Jagielski M, von Kleist M, Ertel W.

PLoS One. 2019 Apr 11;14(4):e0213734. doi: 10.1371/journal.pone.0213734. eCollection 2019.

2.

Reconstruction of the Genetic History and the Current Spread of HIV-1 Subtype A in Germany.

Hanke K, Faria NR, Kühnert D, Yousef KP, Hauser A, Meixenberger K, Hofmann A, Bremer V, Bartmeyer B, Pybus O, Kücherer C, von Kleist M, Bannert N.

J Virol. 2019 May 29;93(12). pii: e02238-18. doi: 10.1128/JVI.02238-18. Print 2019 Jun 15.

PMID:
30944175
3.

The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis.

Duwal S, Seeler D, Dickinson L, Khoo S, von Kleist M.

Front Pharmacol. 2019 Mar 13;10:199. doi: 10.3389/fphar.2019.00199. eCollection 2019.

4.

Analysis of long non-coding RNA and mRNA expression in bovine macrophages brings up novel aspects of Mycobacterium avium subspecies paratuberculosis infections.

Gupta P, Peter S, Jung M, Lewin A, Hemmrich-Stanisak G, Franke A, von Kleist M, Schütte C, Einspanier R, Sharbati S, Bruegge JZ.

Sci Rep. 2019 Feb 7;9(1):1571. doi: 10.1038/s41598-018-38141-x.

5.

Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis.

Duwal S, Dickinson L, Khoo S, von Kleist M.

PLoS Comput Biol. 2019 Jan 30;15(1):e1006740. doi: 10.1371/journal.pcbi.1006740. eCollection 2019 Jan.

6.

Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes.

Duwal S, Dickinson L, Khoo S, von Kleist M.

PLoS Comput Biol. 2018 Jun 14;14(6):e1006155. doi: 10.1371/journal.pcbi.1006155. eCollection 2018 Jun.

7.

In cell mutational interference mapping experiment (in cell MIME) identifies the 5' polyadenylation signal as a dual regulator of HIV-1 genomic RNA production and packaging.

Smyth RP, Smith MR, Jousset AC, Despons L, Laumond G, Decoville T, Cattenoz P, Moog C, Jossinet F, Mougel M, Paillart JC, von Kleist M, Marquet R.

Nucleic Acids Res. 2018 May 18;46(9):e57. doi: 10.1093/nar/gky152.

8.

Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.

Meixenberger K, Yousef KP, Smith MR, Somogyi S, Fiedler S, Bartmeyer B, Hamouda O, Bannert N, von Kleist M, Kücherer C.

Virol J. 2017 Nov 14;14(1):223. doi: 10.1186/s12985-017-0887-1.

9.

In silico cytotoxicity assessment on cultured rat intestinal cells deduced from cellular impedance measurements.

Gupta P, Gramatke A, Einspanier R, Schütte C, von Kleist M, Sharbati J.

Toxicol In Vitro. 2017 Jun;41:179-188. doi: 10.1016/j.tiv.2017.02.021. Epub 2017 Mar 2.

PMID:
28263893
10.

MIMEAnTo: profiling functional RNA in mutational interference mapping experiments.

Smith MR, Smyth RP, Marquet R, von Kleist M.

Bioinformatics. 2016 Nov 1;32(21):3369-3370. Epub 2016 Jul 10.

PMID:
27402903
11.

Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.

Duwal S, Sunkara V, von Kleist M.

CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):377-87. doi: 10.1002/psp4.12095. Epub 2016 Jul 21.

12.

Inferring HIV-1 Transmission Dynamics in Germany From Recently Transmitted Viruses.

Pouran Yousef K, Meixenberger K, Smith MR, Somogyi S, Gromöller S, Schmidt D, Gunsenheimer-Bartmeyer B, Hamouda O, Kücherer C, von Kleist M.

J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):356-363.

PMID:
27400403
13.

Top-down and bottom-up modeling in system pharmacology to understand clinical efficacy: An example with NRTIs of HIV-1.

Duwal S, von Kleist M.

Eur J Pharm Sci. 2016 Oct 30;94:72-83. doi: 10.1016/j.ejps.2016.01.016. Epub 2016 Jan 18.

PMID:
26796142
14.

Mutational interference mapping experiment (MIME) for studying RNA structure and function.

Smyth RP, Despons L, Huili G, Bernacchi S, Hijnen M, Mak J, Jossinet F, Weixi L, Paillart JC, von Kleist M, Marquet R.

Nat Methods. 2015 Sep;12(9):866-72. doi: 10.1038/nmeth.3490. Epub 2015 Aug 3.

PMID:
26237229
15.

Logical-continuous modelling of post-translationally regulated bistability of curli fiber expression in Escherichia coli.

Yousef KP, Streck A, Schütte C, Siebert H, Hengge R, von Kleist M.

BMC Syst Biol. 2015 Jul 23;9:39. doi: 10.1186/s12918-015-0183-x.

16.

Optimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor Settings.

Duwal S, Winkelmann S, Schütte C, von Kleist M.

PLoS Comput Biol. 2015 Apr 30;11(4):e1004200. doi: 10.1371/journal.pcbi.1004200. eCollection 2015 Apr.

17.

Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany.

Meixenberger K, Yousef KP, Somogyi S, Fiedler S, Bartmeyer B, von Kleist M, Kücherer C.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19746. doi: 10.7448/IAS.17.4.19746. eCollection 2014.

18.

Assessment of ambiguous base calls in HIV-1 pol population sequences as a biomarker for identification of recent infections in HIV-1 incidence studies.

Meixenberger K, Hauser A, Jansen K, Yousef KP, Fiedler S, von Kleist M, Norley S, Somogyi S, Hamouda O, Bannert N, Bartmeyer B, Kücherer C.

J Clin Microbiol. 2014 Aug;52(8):2977-83. doi: 10.1128/JCM.03289-13. Epub 2014 Jun 11.

19.

Awareness and utilization of reporting pathways for adverse events following immunization: online survey among pediatricians in Russia and Germany.

Muehlhans S, von Kleist M, Gretchukha T, Terhardt M, Fegeler U, Maurer W, Namazova-Baranova L, Gaedicke G, Baranov A, Rath B.

Paediatr Drugs. 2014 Aug;16(4):321-30. doi: 10.1007/s40272-014-0075-3.

PMID:
24849291
20.

'Time-to-amphotericin B' in cryptococcal meningitis in a European low-prevalence setting: analysis of diagnostic delays.

Katchanov J, von Kleist M, Arastéh K, Stocker H.

QJM. 2014 Oct;107(10):799-803. doi: 10.1093/qjmed/hcu077. Epub 2014 Apr 10.

PMID:
24722846
21.

Quantitative influenza follow-up testing (QIFT)--a novel biomarker for the monitoring of disease activity at the point-of-care.

Chen X, Pouran Yousef K, Duwe S, Karsch K, Grover S, Wählisch S, Obermeier P, Tief F, Mühlhans S, Seeber L, von Kleist M, Schweiger B, Rath B.

PLoS One. 2014 Mar 21;9(3):e92500. doi: 10.1371/journal.pone.0092500. eCollection 2014.

22.

Towards a personalised approach to managing influenza infections in infants and children - food for thought and a note on oseltamivir.

Rath B, Tief F, Karsch K, Muehlhans S, Obermeier P, Adamou E, Chen X, Seeber L, Peiser C, Hoppe C, von Kleist M, Conrad T, Schweiger B.

Infect Disord Drug Targets. 2013 Feb;13(1):25-33.

PMID:
23675924
23.

In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis.

Rath BA, Yousef KP, Katzenstein DK, Shafer RW, Schütte C, von Kleist M, Merigan TC.

PLoS One. 2013 Apr 17;8(4):e61102. doi: 10.1371/journal.pone.0061102. Print 2013.

24.

Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis.

Rath BA, von Kleist M, Castillo ME, Kolevic L, Caballero P, Soto-Castellares G, Amedee AM, Robinson JE, Katzenstein DK, Van Dyke RB, Oberhelman RA.

BMC Infect Dis. 2013 Jan 2;13:1. doi: 10.1186/1471-2334-13-1.

25.

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.

Duwal S, Schütte C, von Kleist M.

PLoS One. 2012;7(7):e40382. doi: 10.1371/journal.pone.0040382. Epub 2012 Jul 11. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/fb73d0f4-1cd8-481d-bddd-20439896102a.

26.

Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses.

Rath B, von Kleist M, Tief F, Karsch K, Tuerk E, Muehlhans S, Louis F, Skopnik H, Schweiger B, Duwe S.

Pediatr Infect Dis J. 2012 Sep;31(9):899-905. doi: 10.1097/INF.0b013e31825c7304.

PMID:
22581220
27.

HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection.

von Kleist M, Metzner P, Marquet R, Schütte C.

PLoS Comput Biol. 2012 Jan;8(1):e1002359. doi: 10.1371/journal.pcbi.1002359. Epub 2012 Jan 19.

28.

Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.

Frank M, von Kleist M, Kunz A, Harms G, Schütte C, Kloft C.

Antimicrob Agents Chemother. 2011 Dec;55(12):5529-40. doi: 10.1128/AAC.00741-11. Epub 2011 Sep 26.

29.

HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs.

von Kleist M, Menz S, Stocker H, Arasteh K, Schütte C, Huisinga W.

PLoS One. 2011 Mar 24;6(3):e18204. doi: 10.1371/journal.pone.0018204.

30.

Drug-class specific impact of antivirals on the reproductive capacity of HIV.

von Kleist M, Menz S, Huisinga W.

PLoS Comput Biol. 2010 Mar 26;6(3):e1000720. doi: 10.1371/journal.pcbi.1000720.

31.

Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine.

von Kleist M, Huisinga W.

Eur J Pharm Sci. 2009 Mar 2;36(4-5):532-43. doi: 10.1016/j.ejps.2008.12.010. Epub 2008 Dec 25.

PMID:
19150497
32.

Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution.

von Kleist M, Huisinga W.

J Pharmacokinet Pharmacodyn. 2007 Dec;34(6):789-806. Epub 2007 Sep 25.

PMID:
17899329

Supplemental Content

Loading ...
Support Center